Enterome And Takeda To Jointly Mine The Microbiome
This article was originally published in Scrip
French company Enterome Bioscience S.A. has further expanded its credentials by inking an alliance with Japan's Takeda Pharmaceutical Company Ltd. to research and develop novel therapeutics aimed at microbiome targets thought to play crucial roles in gastrointestinal disorders.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.